Figure 14. HPS-THRIVE-2. HPS-THRIVE-2 was the third major randomized, blinded, controlled study using niacin (administered with an anti-flush medication called laropiprant) that failed to show any clinical outcome benefit.
Peter Attia: Slight decrease in apoB.
Below is my photo from the article cited by Tom.
These are the most common reasons (side effects) that patients had to stop the combination pill (ERN/LRPT)
This THRIVE trial should not be pointed to as a reason to not use Niacin as it had 20mg of laropiprant in it (added to prevent side effects.
Much of the toxicity is just aggravating glucose. (Tom writes)
The Euro article that Tom refers to does not mention glucose in its abstract.
No comments:
Post a Comment